Table 2 List of some selected miR candidates using chemical modification and their delivery
Target miRs | miR modification | Delivery of therapeutic miRs | Pathophysiological role | Model system | References |
|---|---|---|---|---|---|
miR-16, miR-122, miR-192, miR-194 | 2′-O-Me | Lipid-based | Fibrosis | Mice | [205] |
miR-133 | 2′-O-Me 2′-O-Me | Lipid-based Lentivirus | Hypertrophy Metabolic disturbance | Mice Cardiomyocytes | [144] [244] |
miR-199b | 2′-O-Me | Lipid-based | Fibrosis and functional impairment | Mice | [285] |
miR-34a | LNA+PS LNA | Direct and lipid-based Lentivirus | Myocardial infarction Contractile dysfunction | Mice and cardiomyocytes C57BL/6 mice and cardiomyocytes | [187] [106] |
miR-1 | LNA | Direct and lipid-based | Oxidative stress | C57BL/6 mice and cardiomyocytes | [188] |
miR-208 | 2′-O-Me LNA | Lipid-based Direct | Hypertrophy Heart failure | Mice Rat | [139] [186] |
miR-328 | 2′-O-Me | Lipid-based | Atrial fibrillation | Mice | [242] |
miR-320 | 2′-O-Me 2′-O-Me 2′-O-Me | Lipid-based Lipid-based Lentivirus | Myocardial infarction Impaired angiogenesis Myocardial infarction | Mice MMVEC Rat and cardiomyocytes | [286] [82] [81] |
miR-98 | 2′-O-Me | Adenovirus | Hypertrophy | Ventricular cardiomyocytes | [240] |
miR-328 | LNA | Adenovirus | Atrial fibrillation | C57BL/6 mice | [242] |
miR-590 and miR-199a | 2′-O-Me | AAV and lipid-based | Cardiac functional impairment | Wistar rats and CD1 mice Adult ventricular cardiomyocytes | [251] |
miR-30c | 2′-O-Me | AAV | Impaired autophagy | H9c2 and HEK293 cell db/db mice | [104] |
miR-21 | 2′-O-Me, 2′-O-F/MOE and LNA LNA+PS | Lipid-based and direct Direct | Fibrosis and functional impairment Fibrosis and cardiac remodeling | Mice Mice | [287] [185] |
miR-322 | 2′-O-Me | Lentivirus | Cardiomyocyte apoptosis | Cardiomyocytes | [258] |
miR-137 | 2′-O-Me | Lentivirus | Cardiomyocyte apoptosis | Cardiomyocytes | [259] |